• Dan Lin
  • Willem Talloen
  • Luc Bijnens
  • Hinrich W. H. Göhlmann
  • Dhammika Amaratunga
  • Roel Straetemans
Part of the Use R! book series (USE R)


The development of new and innovative treatments for unmet medical (Barlow et al. 1972) needs is the major challenge in biomedical research. Unfortunately, for the past decade, there has been a steady decline in the number of new therapies reaching the market, despite of the increased investments in pharmaceutical R&D (FDA 2004). One of the most critical steps in a drug discovery program is target identification and validation (Sams-Dodd 2005).


False Positive Finding Inference Step Drug Discovery Program False Positive Gene Specific Biological Pathway 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


  1. Amaratunga & Cabrera, J. (2003). Exploration and Analysis of DNA Microarray and Protein Array Data, New York: John WileyGoogle Scholar
  2. Barlow, R.E., Bartholomew, D.J., Bremner, M.J., & Brunk, H.D. (1972). Statistical inference under order restriction. New York: Wiley.Google Scholar
  3. Butcher, S. (2003). Target discovery and validation in the post-genomic era. Neurochemical Research, 28, 367–377.Google Scholar
  4. Chuang-Stein, C., & Agresti, A. (1997). Tutorial in biostatistics: A review of tests for detecting a monotone dose-response relationship with ordinal response data. Statistics in Medicine, 16, 2599–2618.Google Scholar
  5. Cooke, R.M. (Ed.). (2009). Uncertainty modeling in dose-response. New York: Wiley.Google Scholar
  6. FDA, U. (2004). Innovation or stagnation: Challenge and opportunity on the critical path to new medical products. Silver Spring: US Food and Drug Administation. New York: WileyGoogle Scholar
  7. Goehlmann, H., & Talloen, W. (2009). Gene expression studies using Affymetrix microarrays. Boca Raton: Chapman & Hall/CRC. New York: WileyGoogle Scholar
  8. Jacqmin, P., Snoeck, E., van Schaick, E., Gieschke, R., Pillai, P., Steimer, J.-L., et al. (2007). Modelling response time profiles in the absence of drug concentrations: Definition and performance evaluation of the KPD model. Journal of Pharmacokinetics and Pharmacodynamics, 34, 57–85.Google Scholar
  9. Jacobs, T., Straetmans, R., Molenberghs, G., Bouwknecht, A., & Bijnens, L. (2010). Latent pharmacokinetic time profile to model dose-response survival data. Journal of Biopharmaceutical Statistics, 20(4), 759–767.Google Scholar
  10. Lengauer, T. (2001). Computational biology at the beginning of the post-genomic era. In Informatics—10 years back. 10 years ahead (Vol. 355). Heidelberg: Springer. New York: Wiley.Google Scholar
  11. Louis, T.A. (2009). Math/Stat perspective in Chapter 2: agreement and disagreement, in Cooke, R.M. (Ed.). (2009). Uncertainty modeling in dose-response. New York: Wiley.Google Scholar
  12. Marton, M., DeRisi, J., Bennett, H., Iyer, V., Meyer, M. Roberts, C., Stoughton, R., Burchard, J., Slade, D., & Dai, H. (1998). Drug target validation and idenfication of secondary drug target effects using DNA microarrays. Nature Medicine, 4, 1293–1301.Google Scholar
  13. Ruberg, S.J. (1995a). Dose response studies. I. Some design considerations. Journal of Biopharmaceutical Statistics, 5(1), 1–14.Google Scholar
  14. Ruberg, S. J. (1995b) Dose response studies. II. Analysis and interpretation. Journal of Biopharmaceutical Statistics, 5(1), 15–42.Google Scholar
  15. Sams-Dodd, F. (2005). Target-based drug discovery: Is something wrong? Drug Discovery Today, 10, 139–147.Google Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2012

Authors and Affiliations

  • Dan Lin
    • 1
  • Willem Talloen
    • 2
  • Luc Bijnens
    • 2
  • Hinrich W. H. Göhlmann
    • 2
  • Dhammika Amaratunga
    • 3
  • Roel Straetemans
    • 4
  1. 1.Veterinary Medicine Research and DevelopmentPfizer Animal HealthZaventemBelgium
  2. 2.Janssen Pharmaceutical Companies of Johnson & JohnsonBeerseBelgium
  3. 3.Biostatistics and ProgrammingJanssen Pharmaceutical Companies of Johnson & JohnsonRaritanUSA
  4. 4.Ablynx NVZwijnaardeBelgium

Personalised recommendations